Table 5 Economic results of the models evaluating routine varicella vaccination (2010 EUR, German price level)
Study | Age at vaccination | Dose schedule | Comparator | Health care payer perspective | Societal perspective |
|---|---|---|---|---|---|
Banz et al. [35] | 15 months | 1 | No vaccination | BCR 1.75 | BCR 4.12 |
11-12 yearsa | 1 | No vaccination | BCR 1.13 | BCR 8.44 | |
combined | 1 | No vaccination | BCR 1.70 | BCR 4.10 | |
Banz et al. [51] | 1-2 years | 2 | 2-dose vaccination at 11–15 yearsa | BCR 0.30; EUR 856/LYG | BCR 1.29 |
Beutels et al. [37] | 15 months | 1 | No vaccination | BCR 0.82; EUR 14,700/LYG | BCR 4.60 |
12 yearsa | 1 | No vaccination | BCR 1.94 | BCR 6.02 | |
Bilcke et al. [30] | 1 year (95 % coverage) | 1 | No vaccination | EUR 550–14,140/QALY | NA |
1 year (1st dose, 95 % coverage); 4 years (2nd dose, 90 % coverage) | 2 | No vaccination | EUR 5,240-31,942/QALY | NA | |
1 year (1st dose, 95 % coverage); 11 years (2nd dose, 80 % coverage) | 2 | No vaccination | EUR 5,043-29,775/QALY | NA | |
1 year (1st dose, 50 % coverage); 4 years (2nd dose, 50 % coverage) | 2 | No vaccination | EUR 3,345-23,240/QALY | NA | |
All vaccination options (including and excluding additional HZ vaccination) | 2 | No vaccination | Net QALY loss for many time horizonsb; EUR 36,256-135,961/LYGb | NA | |
Bonanni et al. [36] | 12-18 months | 2 | No vaccination | BCR 0.67 | BCR 3.47 |
13 years | 2 | No vaccination | BCR 0.36 | BCR 2.60 | |
Brisson et al. [31] | 12 months | 1 | No vaccination | BCR 0.61; EUR 38,142/LYG | BCR 5.24 |
12 months | 1 | No vaccination | BCR 0.59c; EUR 40,193/LYGc | BCR 5.09c | |
12 months | 1 | No vaccination | BCR 0.16b; EUR 101,296/LYGb | NA | |
12 yearsa | 1 | No vaccination | BCR 0.73; EUR 15,863/LYG | BCR 4.44 | |
Brisson et al. [32] | Infants | 1 | No vaccination | Net QALY lossb | Net QALY lossb |
11 yearsa | 1 | No vaccination | EUR 26,110/QALYb | Cost-savingb | |
Coudeville et al. [52] | <6 years | 1 | No vaccination | Net benefit EUR 326.8 million | NA |
Coudeville et al. [53] | 12-36 months | 1 | No vaccination | BCR 1.20 at high vaccination coverage | BCR 3.50 at high vaccination coverage |
Coudeville et al. [54] | 12-36 months | 1 | No vaccination | Cost-saving at high vaccination coverage (Germany 51 %; France 6.7 %); EUR 6.960/LYG at low vaccination coverage (France; cost-saving in Germany) | Cost-saving at high vaccination coverage (Germany 61 %; France 60 %) |
DIez Domingo et al. [55] | 15 months | 1 | No vaccination | BCR 0.54 | BCR 1.61 |
Getsios et al. [56] | 12 months | 1 | No vaccination | EUR 71,722/QALY; EUR 36/varicella case avoided | Cost-saving |
Ginsberg & Somekh [57] | 12 months | 1 | No vaccination | BCR 1.63 | BCR 19.33 |
Hammerschmidt et al. [58] | 11-23 months (including a catch-up of 2–17 year oldsa) | 2 (1 dose for catch-up) | 1-dose vaccination at 12–15 yearsa | BCR 1.08 | BCR 2.56 |
Huse et al. [59] | 15 months | 1 | No vaccination | NA | Cost-saving (net benefit of EUR 86.28 per vaccinee) |
Lenne et al. [60] | 1-2 years | 1 | No vaccination | BCR 0.91; EUR 5,202/LYG | BCR 3.70 |
Lieu et al. [61] | <6 years | 1 | No vaccination | BCR 0,90; EUR 21,648/LYG; EUR 5.68/varicella case prevented | BCR 5.40 |
Preblud et al. [62] | 15 months | 1 | No vaccination | BCR 0.30 | BCR 6.90 (including home care costs) |
Scuffham et al. [63] | 15 months | 1 | No routine vaccination but low private coverage | BCR 0.67 | BCR 2.79 |
Scuffham et al. [34] | 12 months | 1 | No vaccination | EUR 49.11/varicella case avoided; EUR 16,439/hospitalisation avoided | NA |
12 yearsa | 1 | No vaccination | EUR 404.81/varicella case avoided; EUR 26,791/hospitalisation avoided | NA | |
Thiry et al. [64] | 11 yearsa | 1 | No vaccination | BCR 0.54; EUR 26,988/LYG | BCR 2.17 |
van Hoek et al. [33] | 1 year (first dose); 3 years (second dose) | 2 | No vaccination | 41 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY)b; 50 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)b | NA |
1 year (first dose); 3 years (second dose) + HZ vaccination of the elderly | 2 | No vaccination | 50 % of the simulations below GBP 20,000/QALY (EUR 26,576/QALY)b; 70 % of the simulations below GBP 30,000/QALY (EUR 39,864/QALY)b | NA | |
Zhou et al. [29] | Children | 1 | No vaccination | BCR 1.00 | BCR 4.37 |
Children | 2 | No vaccination | BCR 0.61 | BCR 2.73 | |
Children | 2 | 1-dose vaccination | BCR 0.13 | BCR 0.56; EUR 95,584/QALY |